The grades of six biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, La Jolla Pharmaceutical Company (LJPC) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
Idenix Pharmaceuticals, Inc. (IDIX) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Idenix Pharmaceuticals is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. For more information, get Portfolio Grader’s complete analysis of IDIX stock.
This week, Incyte Corporation (INCY) pushes up from a C to a B rating. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Progenics Pharmaceuticals, Inc. (PGNX) boosts its rating from a C to a B this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
This week, Celladon Corporation’s (CLDN) ratings are up from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
Cerulean Pharma, Inc. (CERU) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of CERU stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
